- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- EGFR positive
- KRAS positive
- PR positive
- PR negative
- ER negative
- BRAF positive
- EGFR negative
- PD-L1 negative
- CD19 positive
- IDH positive
- HLA-A positive
- p16 positive
- ALK negative
- ALK positive
- CD20 positive
- BRCA1 positive
- BRCA2 positive
- HLA positive
- MET positive
- IDH negative
- ROS1 positive
- TP53 positive
- MYC positive
- MSI-H positive
- FLT3 positive
- HLA negative
- p16 negative
- HR positive
- ROS1 negative
- BRAF negative
- PALB2 positive
- NRAS positive
- RB1 negative
- RB1 positive
- HLA-A negative
- dMMR positive
- HPV positive
- PIK3CA positive
- NF1 positive
- BRCA positive
- RET positive
- CD22 positive
- MET negative
- RAS positive
- BCL2 positive
- NTRK positive
- MGMT negative
- ATM positive
- BCL6 positive
- HPV negative
- CD30 positive
- ARID1A positive
- KRAS negative
- MMR positive
- anti-dsDNA positive
- BCR-ABL1 positive
- KIT positive
- Philadelphia chromosome positive
- ANA positive
- CCND1 positive
- CFTR positive
- HRAS positive
- MGMT positive
- MLH1 positive
- MSH6 positive
- NPM1 positive
- CD123 positive
- MSH2 positive
- PD-1 positive
- PMS2 positive
- PTEN positive
- RAS negative
- ctDNA positive
- CD33 positive
- CHEK2 positive
- FGFR2 positive
- KMT2A positive
- RAD51 positive
- BRIP1 positive
- HBV DNA negative
- HbSS positive
- MTAP positive
- NTRK1 positive
- RET negative
- FGFR3 positive
- HBsAg positive
- MSI positive
- MSS positive
- PD-1 negative
- anti-Sm positive
- AR positive
- ASXL1 positive
- BRCA negative
- CDK4 positive
- CLDN18.2 positive
- FGFR positive
- GPC3 positive
- HBV DNA positive
- HBsAg negative
- MMR negative
- MSI negative
- MSI-H negative
- NF2 positive
- NRAS negative
- RUNX1 positive
- STK11 positive
- TP53 negative
- p53 positive
- t(11;14) positive
- CD3 positive
- FANCA positive
- HPV16 positive
- MSS negative
- NTRK negative
- RAD51C positive
- BCR-ABL positive
- CD19 negative
- CD4 positive
- DMD positive
- EZH2 positive
- FLT3 negative
- HR negative
- JAK2 positive
- PDGFRA positive
- RAD51D positive
- RAF positive
- SMARCA4 positive
- SMN1 positive
- T790M positive
- ZnT8 positive
- dMMR negative
- ABCA4 positive
- APC positive
- BAP1 positive
- BARD1 positive
- BRCA1 negative
- BRCA2 negative
- CCNE1 positive
- CD4 count positive
- CD5 positive
- CD70 positive
- CDK12 positive
- DLL3 positive
- Del(17p) positive
- EBV positive
- EPCAM positive
- FMR1 positive
- GATA2 positive
- GRN positive
- HBcAb negative
- IA-2 positive
- Ki-67 positive
- MECP2 positive
- NF1 negative
- PTEN negative
- PTPN11 positive
- Ph positive
- RAD54L positive
- RF positive
- TERT positive
- TROP2 positive
- pMMR positive
- t(14;16) positive
- t(4;14) positive
- t(9;22) positive
- \-7 positive
- AKT1 positive
- APOE ε4 positive
- APOL1 positive
- B7-H3 positive
- CD38 positive
- CDK6 positive
- CEA positive
- CHEK1 positive
- CLDN6 positive
- COL7A1 positive
- DMPK positive
- DNMT3A positive
- ER or PR positive
- FANCL positive
- FRα positive
- H3K27M positive
- HBB positive
- HBcAb positive
- HRD positive
- HbSC positive
- HbSβ0-thalassemia positive
- L858R positive
- MDM2 positive
- MLH1 negative
- MLL rearrangement positive
- MSH2 negative
- MSH6 negative
- NBN positive
- PIK3CA negative
- PMS2 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Activity Modification
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Adverse Event from Previous Treatment (Excluding Alopecia, Cutaneous Toxicity, Peripheral Neuropathy, Fatigue Grade ≤ 2)
- Alectinib for ALK
- Allogeneic Hematopoietic Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplant using Bone Marrow, Peripheral Blood, or Umbilical Cord Stem Cells
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
12782 trials
1
2
3
…50